nonviral delivery
Recently Published Documents


TOTAL DOCUMENTS

60
(FIVE YEARS 2)

H-INDEX

23
(FIVE YEARS 0)

2021 ◽  
Vol 4 (9) ◽  
pp. e202000875
Author(s):  
Kathleen M McAndrews ◽  
Fei Xiao ◽  
Antonios Chronopoulos ◽  
Valerie S LeBleu ◽  
Fernanda G Kugeratski ◽  
...  

CRISPR/Cas9 is a promising technology for gene editing. To date, intracellular delivery vehicles for CRISPR/Cas9 are limited by issues of immunogenicity, restricted packaging capacity, and low tolerance. Here, we report an alternative, nonviral delivery system for CRISPR/Cas9 based on engineered exosomes. We show that non-autologous exosomes can encapsulate CRISPR/Cas9 plasmid DNA via commonly available transfection reagents and can be delivered to recipient cancer cells to induce targeted gene deletion. As a proof-of-principle, we demonstrate that exosomes loaded with CRISPR/Cas9 can target the mutant KrasG12D oncogenic allele in pancreatic cancer cells to suppress proliferation and inhibit tumor growth in syngeneic subcutaneous and orthotopic models of pancreatic cancer. Exosomes may thus be a promising delivery platform for CRISPR/Cas9 gene editing for targeted therapies.


Author(s):  
Amr A. Abdeen ◽  
Brian D. Cosgrove ◽  
Charles A. Gersbach ◽  
Krishanu Saha

The recent discovery and subsequent development of the clustered regularly interspaced short palindromic repeat (CRISPR)–CRISPR-associated (Cas) platform as a precise genome editing tool have transformed biomedicine. As these CRISPR-based tools have matured, multiple stages of the gene editing process and the bioengineering of human cells and tissues have advanced. Here, we highlight recent intersections in the development of biomaterials and genome editing technologies. These intersections include the delivery of macromolecules, where biomaterial platforms have been harnessed to enable nonviral delivery of genome engineering tools to cells and tissues in vivo. Further, engineering native-like biomaterial platforms for cell culture facilitates complex modeling of human development and disease when combined with genome engineering tools. Deeper integration of biomaterial platforms in these fields could play a significant role in enabling new breakthroughs in the application of gene editing for the treatment of human disease. Expected final online publication date for the Annual Review of Biomedical Engineering, Volume 23 is June 2021. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.


Pharmaceutics ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 1233
Author(s):  
Dongyoon Kim ◽  
Quoc-Viet Le ◽  
Yina Wu ◽  
Jinwon Park ◽  
Yu-Kyoung Oh

Genome-editing technology has emerged as a potential tool for treating incurable diseases for which few therapeutic modalities are available. In particular, discovery of the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system together with the design of single-guide RNAs (sgRNAs) has sparked medical applications of genome editing. Despite the great promise of the CRISPR/Cas system, its clinical application is limited, in large part, by the lack of adequate delivery technology. To overcome this limitation, researchers have investigated various systems, including viral and nonviral vectors, for delivery of CRISPR/Cas and sgRNA into cells. Among nonviral delivery systems that have been studied are nanovesicles based on lipids, polymers, peptides, and extracellular vesicles. These nanovesicles have been designed to increase the delivery of CRISPR/Cas and sgRNA through endosome escape or using various stimuli such as light, pH, and environmental features. This review covers the latest research trends in nonviral, nanovesicle-based delivery systems that are being applied to genome-editing technology and suggests directions for future progress.


2020 ◽  
Vol 32 (46) ◽  
pp. 2003537 ◽  
Author(s):  
Jing Gong ◽  
Hong‐Xia Wang ◽  
Yeh‐Hsing Lao ◽  
Hanze Hu ◽  
Naazanene Vatan ◽  
...  

2020 ◽  
Vol 20 (2) ◽  
pp. 142-151
Author(s):  
Miaojin Zhou ◽  
Zhiqing Hu ◽  
Chunhua Zhang ◽  
Lingqian Wu ◽  
Zhuo Li ◽  
...  

Hemophilia A (HA) is a hereditary hemorrhagic disease caused by a deficiency of coagulation factor VIII (FVIII) in blood plasma. Patients with HA usually suffer from spontaneous and recurrent bleeding in joints and muscles, or even intracerebral hemorrhage, which might lead to disability or death. Although the disease is currently manageable via delivery of plasma-derived or recombinant FVIII, this approach is costly, and neutralizing antibodies may be generated in a large portion of patients, which render the regimens ineffective and inaccessible. Given the monogenic nature of HA and that a slight increase in FVIII can remarkably alleviate the phenotypes, HA has been considered to be a suitable target disease for gene therapy. Consequently, the introduction of a functional F8 gene copy into the appropriate target cells via viral or nonviral delivery vectors, including gene correction through genome editing approaches, could ultimately provide an effective therapeutic method for HA patients. In this review, we discuss the recent progress of gene therapy for HA with viral and nonviral delivery vectors, including piggyBac, lentiviral and adeno-associated viral vectors, as well as new raising issues involving liver toxicity, pre-existing neutralizing antibodies of viral approach, and the selection of the target cell type for nonviral delivery.


Pharmaceutics ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 759
Author(s):  
Francesco Aulicino ◽  
Julien Capin ◽  
Imre Berger

DNA delivery is at the forefront of current research efforts in gene therapy and synthetic biology. Viral vectors have traditionally dominated the field; however, nonviral delivery systems are increasingly gaining traction. Baculoviruses are arthropod-specific viruses that can be easily engineered and repurposed to accommodate and deliver large sequences of exogenous DNA into mammalian cells, tissues, or ultimately organisms. These synthetic virus-derived nanosystems (SVNs) are safe, readily customized, and can be manufactured at scale. By implementing clustered regularly interspaced palindromic repeats (CRISPR) associated protein (CRISPR/Cas) modalities into this system, we developed SVNs capable of inserting complex DNAs into genomes, at base pair precision. We anticipate a major role for SVNs as an attractive alternative to viral vectors in accelerating genome engineering and gene therapy applications in the future.


2020 ◽  
Vol 4 (8) ◽  
pp. 2000059
Author(s):  
Mao Mao ◽  
Chun‐Chi Chang ◽  
Adrian Pickar‐Oliver ◽  
Lisa D. Cervia ◽  
Liangli Wang ◽  
...  

2020 ◽  
Vol 20 ◽  
pp. 661-672 ◽  
Author(s):  
Yuan Rui ◽  
Mahita Varanasi ◽  
Shanelle Mendes ◽  
Hannah M. Yamagata ◽  
David R. Wilson ◽  
...  

2020 ◽  
Vol 25 (6) ◽  
pp. 1065-1073 ◽  
Author(s):  
Serge Mignani ◽  
Xangyang Shi ◽  
Valentin Ceña ◽  
Jean-Pierre Majoral

2020 ◽  
Vol 6 (21) ◽  
pp. eaba2983 ◽  
Author(s):  
Wujin Sun ◽  
Jinqiang Wang ◽  
Quanyin Hu ◽  
Xingwu Zhou ◽  
Ali Khademhosseini ◽  
...  

CRISPR-Cas12a represents an efficient tool for genome editing in addition to the extensively investigated CRISPR-Cas9. However, development of efficient nonviral delivery system for CRISPR-Cas12a remains challenging. Here, we demonstrate a DNA nanoclew (NC)–based carrier for delivery of Cas12a/CRISPR RNA (crRNA) ribonucleoprotein (RNP) toward regulating serum cholesterol levels. The DNA NC could efficiently load the Cas12a/crRNA RNP through complementation between the DNA NC and the crRNA. Addition of a cationic polymer layer condensed the DNA-templated core and allowed further coating of a charge reversal polymer layer, which makes the assembly negatively charged under a physiological pH but reverts to positive charge under an acidic environment. When Pcsk9 was selected as the target gene because of its important role in regulating the level of serum cholesterol, efficient Pcsk9 disruption was observed in vivo (~48%), significantly reducing the expression of PCSK9 and gaining the therapeutic benefit of cholesterol control (~45% of cholesterol reduction).


Sign in / Sign up

Export Citation Format

Share Document